• CHMP recommends EU authorization of Ascendis Pharma’s once-weekly TransCon CNP for achondroplasia in children aged two or older with open epiphyses.
• A final European Commission decision is expected in the fourth quarter of 2026.
• If authorized, the first EU launch is planned in Germany in the first quarter of 2027 under the YUVIWEL brand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610160829PRIMZONEFULLFEED9847367) on October 16, 2026, and is solely responsible for the information contained therein.